190 related articles for article (PubMed ID: 16276512)
1. Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.
Aybar A; Krause JR
Microsc Res Tech; 2005 Nov; 68(3-4):247-9. PubMed ID: 16276512
[TBL] [Abstract][Full Text] [Related]
2. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
[TBL] [Abstract][Full Text] [Related]
3. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus.
Herbst H; Samol J; Foss HD; Raff T; Niedobitek G
J Pathol; 1997 Jul; 182(3):299-306. PubMed ID: 9349232
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander.
Oudejans JJ; Jiwa NM; Meijer CJ
J Pathol; 1997 Apr; 181(4):353-6. PubMed ID: 9196428
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility complex (MHC)-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr Virus (EBV).
Tzardi M; Kouvidou C; Papakonstantinou E; Datseris G; Darivianaki K; Karidi E; Eliopoulos G; Delidis G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(2):827-31. PubMed ID: 8687136
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.
Glavina-Durdov M; Jakic-Razumovic J; Capkun V; Murray P
Br J Cancer; 2001 May; 84(9):1227-34. PubMed ID: 11336475
[TBL] [Abstract][Full Text] [Related]
9. Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease.
Knecht H; Berger C; McQuain C; Rothenberger S; Bachmann E; Martin J; Esslinger C; Drexler HG; Cai YC; Quesenberry PJ; Odermatt BF
Oncogene; 1999 Nov; 18(50):7161-7. PubMed ID: 10597317
[TBL] [Abstract][Full Text] [Related]
10. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.
Marshall NA; Culligan DJ; Tighe J; Johnston PW; Barker RN; Vickers MA
Exp Hematol; 2007 Apr; 35(4):596-604. PubMed ID: 17379070
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
12. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.
Diepstra A; Poppema S; Boot M; Visser L; Nolte IM; Niens M; Te Meerman GJ; van den Berg A
Tissue Antigens; 2008 Mar; 71(3):219-26. PubMed ID: 18257895
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus.
Herbst H; Raff T; Stein H
J Pathol; 1996 May; 179(1):54-9. PubMed ID: 8691346
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus expression in Hodgkin's disease in Jordan.
Almasri NM; Khalidi HS
Saudi Med J; 2004 Jun; 25(6):770-5. PubMed ID: 15195209
[TBL] [Abstract][Full Text] [Related]
15. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease.
Dukers DF; Jaspars LH; Vos W; Oudejans JJ; Hayes D; Cillessen S; Middeldorp JM; Meijer CJ
J Pathol; 2000 Feb; 190(2):143-9. PubMed ID: 10657011
[TBL] [Abstract][Full Text] [Related]
16. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease.
Oudejans JJ; Jiwa NM; Kummer JA; Horstman A; Vos W; Baak JP; Kluin PM; van der Valk P; Walboomers JM; Meijer CJ
Blood; 1996 May; 87(9):3844-51. PubMed ID: 8611711
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus infection and bcl-2 proto-oncogene expression. Separate events in the pathogenesis of Hodgkin's disease?
Khan G; Gupta RK; Coates PJ; Slavin G
Am J Pathol; 1993 Nov; 143(5):1270-4. PubMed ID: 8238244
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Hodgkin's disease.
Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus (EBV) and Hodgkin's disease in children: incidence of EBV latent membrane protein in malignant cells.
Weinreb M; Day PJ; Murray PG; Raafat F; Crocker J; Parkes SE; Coad NA; Jones JT; Mann JR
J Pathol; 1992 Dec; 168(4):365-9. PubMed ID: 1336543
[TBL] [Abstract][Full Text] [Related]
20. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
